Caris Life Sciences (CAI) Share-based Compensation (2024 - 2026)

Caris Life Sciences' Share-based Compensation history runs 3 years deep, the most recent figure standing at $15.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 8.04% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $71.2 million (changed N/A YoY), while the FY2025 annual figure was $70.0 million, up 275.51% from the prior year.
• Share-based Compensation was $15.9 million for Q1 2026 at Caris Life Sciences, up from $13.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $28.3 million in Q2 2025 to a low of $4.7 million in Q3 2024.
• Historically, Share-based Compensation has averaged $13.7 million across 3 years, with a median of $13.7 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation surged 189.12% in 2025, then grew 8.04% in 2026.
• A 3-year view of Share-based Compensation shows it stood at $5.0 million in 2024, then surged by 168.58% to $13.4 million in 2025, then grew by 18.74% to $15.9 million in 2026.
• The last three Share-based Compensation figures came in at $15.9 million (Q1 2026), $13.4 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.